Conference
A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)
Authors
Ellis PM; Chu QS; Leighl NB; Laurie SA; Trommeshauser D; Hanft G; Munzert G; Gyorffy S
Volume
26
Pagination
pp. 8115-8115
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2008
DOI
10.1200/jco.2008.26.15_suppl.8115
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X